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This is a report on a workshop titled ‘Ethics for genomic research across five African countries: Guidelines,
experiences and challenges’, University of the Witwatersrand, Johannesburg, South Africa, 10 and 11 December
2012. The workshop was hosted by the Wits-INDEPTH partnership, AWI-Gen, as part of the H3Africa Consortium.
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Data sharing and benefit sharing, Burkina faso, Ghana, Kenya, South Africa, TanzaniaOne of the primary ethical challenges to genomic re-
search in Africa pertains to sensitivities and questions
raised by communities based on their prior experiences
as well as regional cultural beliefs and practices. In order
for genomic research in Africa to be successful, issues
like community engagement, broad consent, and the im-
plications of sharing DNA samples and genetic data need
to be debated and the potential risks of stigmatisation and
harm need to be considered carefully. Ultimately, these
ethical challenges need to be weighed against strategies
and approaches making use of genomic research in ad-
dressing the high burden of disease in Africa.
Background to the workshop
The Wits-INDEPTH (University of the Witwatersrand -
International Network for the Demographic Evaluation
of Populations and Their Health in Low- and Middle-
Income Countries) Collaborative Centre, known by the
abbreviation AWI-Gen (Africa Wits-INDEPTH Partner-
ship for the Genomic Research), was established in 2012
under the auspices of the Human Health and Heredity
in Africa (H3Africa) Consortium. In bringing together a* Correspondence: michele.ramsay@wits.ac.za
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reproduction in any medium, provided the ormultidisciplinary team of researchers, AWI-Gen is well
poised to embark on a study of cardiometabolic disease
risk in Africa. More specifically, the project aims to iden-
tify genetic factors that contribute to body compos-
ition, including obesity, which together with environmental
factors, contribute to susceptibility for cardiometabolic
diseases.
The partnership includes five health and demographic
surveillance system (HDSS) field sites of the INDEPTH
Network (www.indepth-network.org) across four coun-
tries, Ghana, Burkina Faso, Kenya and South Africa, and
an urban study site in Soweto (Birth to Twenty and other
studies within the Developmental Pathways for Health
Research Unit at the University of the Witwatersrand,
Johannesburg). The HDSS centres offer established in-
frastructure, trained fieldworkers, long-standing commu-
nity engagement and detailed longitudinal phenotypic
data. The key strengths of the study are harmonised phe-
notyping across sites, building on strong existing cohorts
and representation of the geographic and social variability
of African populations. This research requires a different
type of involvement with the research participants, to that
which has been conducted previously by INDEPTH. Since
participants are required to consent to donating blood
samples with broad consent and to biobanking of the bio-
logical samples, many challenges exist in communicating
this information to the participants and understanding thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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whom we plan to conduct the research.
To gain a better understanding of the ethical chal-
lenges relating to our genomic work, we invited mem-
bers of ethics committees and researchers from the
various regions in Africa we work in to a workshop in
Johannesburg to discuss and map the ethico-legal research
environment in these countries. Among the issues given
priority were community engagement, informed consent,
sample and data sharing, as well as benefit sharing.
Since all participating research groups have to satisfy
the requirements of their institutional (and in some
cases national) ethics committees in keeping with their
country's policies, this workshop, hosted by AWI-Gen,
was intended to stimulate discussion among African
scholars and to raise the importance of growing and
shaping the landscape of genomic research on the
African continent in a favourable way.
Workshop focus
The rationale for inviting members of ethics committees
was to provide oversight to each of our participating
institutions and also included Tanzania, as a potential
future partner in our genomic research. Where appropri-
ate, we attempted to invite individuals from institutional
and national review committees. We asked participants to
prepare a presentation on aspects of the ethical and legal
context in their countries pertinent to genomics research.
Specifically, we asked meeting invitees to consider the
question: ‘How would ethics review committees in your
country view genomic research and what issues would
most influence their decision to approve such research?’
The purpose of these presentations was to develop a bet-
ter understanding of potential bottlenecks and pertinent
ethical issues in genomic research in Africa. In order to
frame the discussions for the second part of the workshop,
we invited an experienced ethicist (JdV) who was involved
in the MalariaGen Project to highlight some of the ethical
challenges they faced and how they addressed them. In
the afternoon, we had breakaway sessions in which partici-
pants were asked to form small groups of five to eight to
discuss one of four topics of ethical importance that we
had identified. These were community engagement, broad
informed consent, sample and data sharing and benefit
sharing.
Ethical oversight and perspectives
Members from the ethics review committees for each
participant country gave an overview of the ethico-legal
framework for research in their countries (summarised
in Table 1) and provided insight into their processes and
experiences. Several common concerns were raised. In par-
ticular, with reference to genomic research, these included
the broad themes of participant protection, managementand sharing of data and samples and appropriate recogni-
tion for the work of local scientists.
Some countries require both institutional and national
ethics approval (Burkina Faso and Kenya). In Kenya, na-
tional approval is provided by accredited ethics review
committees which are hosted by several research institu-
tions. In Ghana, institutional review is followed by sub-
mission to the Ghana Health Service Ethical Review
Board if the research facility is part of the Ghana Health
Service. South African researchers only require institu-
tional approval, and in Tanzania, only national approval
is required. In Ghana and Kenya, institutional scientific
review of the research projects precedes ethical review.
These differences likely reflect the size and complexity
of the research communities. There was a suggestion
that the processes in some of the countries may change
in the future.
Most of the ethics committees require a description of
the informed consent process to be followed during re-
cruitment, together with how confidentiality and ano-
nymity will be maintained and how data and samples
will be stored and distributed. In addition, some coun-
tries placed an emphasis on a demonstration of local
capacity development, and others were concerned about
the clear justification of the amount of sample (e.g.
blood) collected and how this would be used. There
were differences in the approachability of committees in
different countries; some actively encouraged applicants
to attend ethics meetings to assist with explaining the
study in response to the questions raised by the commit-
tee members (e.g. in the case of the Navrongo Institu-
tional Review Board (IRB)). This provided an important
educational opportunity for both IRB members and re-
searchers. A challenge in the multilingual communities
in Africa is the translation of information sheets, con-
sent forms and questionnaires into local languages. In
the case of Francophone countries (e.g. Burkina Faso),
the full research protocols need to be translated into
French.
In some of the countries, the ethics committees per-
form a monitoring function (e.g. in Ghana genetic and
genomic studies as well as clinical trials are monitored
by visits to research sites), but in others, logistical and
costing constraints inhibited rigorous monitoring. Some
ethics committees routinely charged for ethics review,
whereas others would do so only in the case of external
applications.
A valuable resource on the laws, regulations and guide-
lines on the protection of human subjects for research
is available from the ‘Compilation of Human Research
Standards’ (2012 Edition) (Office for Human Research
Protections, U.S. Department of Health and Human
Services). (http://www.hhs.gov/ohrp/international/intlcompi
lation/intlcompilation.html). The 2012 version includes
Table 1 Regulatory framework for ethics approval for biomedical research in five African countries
Countrya Institutional and national ethics review
boards
Process for approval of genomic
research
Legislation
Burkina Faso Institutional review (only three in the
country) and national review (National
Ethics Committee, constituted in 2002,
Ministry of Health)
Sequential manner (institutional and then
national) (submitted in French)
Under auspices of the Ministry of Health
Ghana Each health research institute has its own
institutional review and institutions that fall
under the Ghana Health Service also
require additional review by the Ghana
Health Service Ethical Review Board in
Accra
Scientific approval from the institution
precedes submission for ethics review
Ghana Health Service
Data protection Act (2012)
For international projects, an appendix
with the Ghana specific protocol must be
submitted
Sequential submission for review
Kenya Institutional review and nationally
accredited ethics review boards
Institutional Scientific Steering Committee
approval prior to submission for
Institutional Ethics review. National review
is done at the research institutions with
accredited ethics review committees
Science and Technology Act (2001)
(Previously Kenya Medical Research
Institute (KEMRI) Ethics Review Committee
approval required for biomedical research)
National Council for Science and
Technology (NCST) Guidelines for Ethical
Conduct of Biomedical Research Involving
Human Subjects in Kenya (2004)
Ministry of Health (MOH) - Human
Biological Materials
South Africa Universities and the medical research
council have their own institutional ethics
committees
Only need approval from institutional
ethics committee (hospital-based research
requires additional approval from the
hospital and research in rural communities
requires provincial approval)
National Health Act No. 61 (2003)
National Research Ethics Council
(http://www.nhrec.org.za)
Export permit required from the
Department of Health for biological sample
transfer
Medical Research Council: Guidelines on
Ethics in Medical Research: General
Principles (2002)
Tanzania National Health Research Ethics Committee
(NHREC) (2002)
Application directly to the NHREC Ministry of Health (MOH)
National Institute for Medical Research
(NIMR), National Health Research Ethics
Committee (NHREC)
NIMR responsible for coordination of
Health Research in Tanzania and
coordination of Formation of Institutional
Health Research Committees to Formally
Approve for Local Health Research
National Institute for Medical Research, Act
of Parliament No. 23, of 1979
Tanzania Commission for Science and
Technology, Act No. 7 of 1986 (COSTECH)
COSTECH Guidelines on Research Permits
and Clearance (2006)
DNA Act (Act No. 8/09) (2009) Provides
guidelines and oversight for laboratories
that work with DNA
aThe following workshop participants provided information from their countries: Burkina Faso, Dr Bocar Kouyaté (Chairman of the National Ethics Committee,
Ministry of Health) and Dr Abdoulaye Ouédraogo (Chairman of the IEC, Centre Muraz); Ghana, Dr Cynthia Bannerman and Mr Kofi Wellington (Ghana Health
Service Ethical Review Committee); Kenya, Dr Christine Wassuna (Kenyan Medical Research Institute (KEMRI) Ethics Review Committee); South Africa, Dr Yosuf
Veriava (Steve Biko Centre for Biomedical Ethics, University of the Witwatersrand); Tanzania, Dr Thomas Nyambo (Member, National Heath Research Ethical
Committee (NHREC), Tanzania) and Dr Geoffrey Somi (Deputy Chair, NHREC).
Ramsay et al. Human Genomics 2014, 8:15 Page 3 of 6
http://www.humgenomics.com/content/8/1/15information from 14 African countries, including Kenya,
South Africa and Tanzania, but not Burkina Faso and
Ghana.Breakaway sessions
During the breakaway sessions, participants were en-
couraged to highlight some of the key ethical issues they
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they had been involved with, or had reviewed, and to
propose recommendations they may provide to over-
come the problems or challenges.Community engagement
Identifying a ‘community’ and its leadership can be diffi-
cult, especially in urban areas. It is important to engage
with local health services and to be mindful that in many
African communities, ‘blood’ has a cultural context that
needs to be understood and taken into consideration
when engaging with research participants. Fundamental
to the success of all projects is ‘respect’ for people and
recognition of the various levels of literacy. Recognising
the hierarchies that exist within communities is impor-
tant in the process of engagement. Engaging through
dialogue at each level is important to establish the ‘rules
of engagement’ at the onset of commencement of
genomic research. Moreover, it is essential that there is
effective communication, with easy to understand infor-
mation, so that expectations are met by appropriate
actions. There was general agreement that when com-
munity approval was granted through a process of inter-
action with stakeholders (e.g. in the villages, in the case
of rural studies), this would not supersede individual in-
formed consent, and potential participants could still de-
cline participation. Potential misconceptions should be
actively addressed and stigmatisation minimised.Informed and broad consent
There was an agreement that care should be taken in
explaining the nature of the research and potential risks
in such a way that they can be understood across differ-
ent educational levels and cultures. Informed consent
would need to be specifically tailored to communities to
take this into consideration and information should be
translated into local languages as necessary. The concept
on broad consent was not familiar to all the participants
at the workshop. When seeking ‘broad’ informed con-
sent, participants are required to consent to the use of
biological samples and associated data collected for the
specified research by the researchers as well as giving
their consent for the sharing of samples and data across
national borders for future research. In most instances,
the research associated with the latter will be unknown
to the research team collecting the samples and having
the contact with participants. However, the researchers
will communicate to participants that future use of their
samples and data will be overseen by review processes
set up by the H3Africa Consortium. Participants will
have an opportunity to ask questions to clarify misun-
derstandings and will be advised that they have the op-
portunity to withdraw should they wish to.There were clear concerns about requesting consent
to perform studies that could not be stipulated in the in-
formation sheet and also for the wide sharing of data
and samples. Some workshop participants found this un-
acceptable and emphasised that although they understood
that it would not be feasible to return to individual partici-
pants for re-consenting, they would be more comfortable
if all requests for the use of samples over and above the
original study request were referred back to the ethics
committee concerned with providing the initial approval
for the study. The question as to whether it would be rea-
sonable, in the case of AWI-Gen, for Wits as central co-
ordinator of the study, to act as custodian for the study
was raised. We did not reach consensus on the question
of broad consent for the sharing of samples and data and
who should be responsible for making the decisions.
The issue of who the study participants should be and
how they should be chosen was raised. In the case where
there is not a clear clinical focus (e.g. patients with a
specific disease), but the target groups consist of ran-
domly chosen individuals from specific geographic areas,
the group felt that there should be an attempt at equity
in choosing participants (e.g. randomization). Strategies
would need to be developed to ensure that there is no
discrimination applied.
Questionnaires and questions should be carefully
aligned with the objectives of the research study. Creat-
ing an expectation of health-related feedback to individ-
uals should be avoided and addressed directly with the
participants at the outset of the project. Community feed-
back and providing a context for the research findings is
important. The question of whether participants should
be informed of findings that are unrelated to the study,
but that may impact their health or that of their children
(e.g. sickle cell carrier status), was hotly debated. There
was, however, general agreement that when appropriate,
participants who require medical care based on pheno-
typic findings (e.g. high blood pressure) should be referred
to the national health system infrastructure.
Sample and data sharing
A characteristic of genomic research generally, and of
our project more specifically, is that it usually involves
international collaboration. In addition, funding condi-
tions for AWI-Gen require us to make data and samples
available for secondary analysis and use. It was recog-
nised that there is a need to balance access with the
interests of the participants, the ethics committees (in
their capacity as protectors of participants) and the fun-
ders and that sharing needed to be a two-way process.
Many workshop participants had not previously en-
countered or reviewed research of this nature, and not
all the participants felt confident that their countries and
committees had developed adequate policy frameworks
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it would be very important to clarify ownership over
resources, most notably regarding samples. A question
arose about whether ownership rested with individual
participants, research groups or their institutions and
countries. The group also questioned whether and how
ownership would be transferred in the case of secondary
use. When samples are shared, this needs to be done in
accordance with the legislative requirements of the
different countries. In the experience of the workshop
participants, material transfer agreements (MTAs) are
considered a good tool to facilitate international shar-
ing of samples whilst protecting the interests of the
local institutions. It was felt that there needs to be appro-
priate recognition of the contribution of local researchers
and institutions (including infrastructure and personnel
costs) when samples are shared. Authorship and ac-
knowledgement in publications is therefore important,
and guidelines need to be developed and outcomes
documented.
During the discussions, several of the ethics committee
members emphasised that they would require ethics re-
view committee approval or permission for secondary
use of samples for projects not stipulated in the original
applications. This raises a potential conflict (or logistical
challenge) within the H3Africa Consortium, where the
intention is to have centralised consortium-specific data
and sample access processes where individual project
leaders may not be directly represented. Further explor-
ation toward a solution will require wider debate.
Although there was consensus that it is necessary to
share samples for large international research studies
across national borders, there were country-specific stip-
ulations. In Kenya, clear justification needs to be made
for why research cannot be done in Kenya before per-
mission is granted to export samples out of the country.
In South Africa, an export permit is required from the
National Department of Health. Material transfer agree-
ments and memoranda of understanding were consid-
ered important tools to ensure appropriate regulation
with regard to sample and data sharing.
Benefit sharing
The question of how genomic research can benefit the
people and populations it involves is pertinent, particu-
larly in the African continent where many communities
continue to live in poverty. However, it is not straight-
forward to determine exactly what would constitute
‘benefit’ and how and who this should be shared with.
The group identified a number of stakeholders that ought
to be considered, including research participants, their
communities, the broader patient group or society and the
research community (local, national and international).
For the AWI-Gen project, and possibly for H3Africaresearch more widely, the focus on African leadership
and capacity development could constitute the primary
form of non-scientific benefit out of this research. In
addition, it was suggested that recruitment could be ac-
companied by information about the health implica-
tions of obesity. This is particularly relevant in the case
of AWI-Gen, which focuses on a growing public health
problem in Africa. Knowledge about the dangers of ex-
cess body fat is still limited, and meeting participants
felt that AWI-Gen could provide some additional bene-
fit through public education. Similarly, a project like
AWI-Gen could link to existing patient organisations to
provide relevant information. A last important issue of
concern - often reflected in ethics discussions in Africa -
relates to the use of genomic samples and data to generate
commercially valuable products. Meeting participants gen-
erally felt that if this was to happen, then research partici-
pants or their communities should have an opportunity to
benefit from or share in such financial gain.Summary
Robust discussion and debate suggested that more dis-
cussion is necessary across participant countries to en-
sure a common understanding of genomic research and
wide sharing of samples and data. Such discussions need
to be premised on a thorough knowledge of genomics
and global trends toward open and wide access. In many
African countries, national guidelines and regulations for
research are relatively broad, without providing insight
into genomic research, and the individual ethics com-
mittees make independent decisions. Among participant
countries, some ethics committees (Kenya and South
Africa) have considerable experience in reviewing gen-
omic projects, but in others, little expertise currently ex-
ists. All, however, indicated a need to further strengthen
capacity for reviewing genomic projects in line with na-
tional and international guidelines for good practice and
to ensure maximum benefit to participant communities.
The H3Africa Consortium is providing a platform to
discuss and debate the issues that have been raised and
is developing policies and guidelines that will be import-
ant in a much wider context for genomic research in de-
veloping countries. Its prime objective is to promote
genomic research capability on the African continent for
the benefit of the health of its people and the global
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